{
    "sec_cik": "0000816284",
    "sec_company_name": "CELGENE CORP /DE/ (Filer)",
    "document_type": "EX991",
    "sec_form_header": "Form 8-K",
    "sec_period_of_report": "20170126",
    "sec_filing_date": "20170126",
    "sec_changed_date": "20170126",
    "sec_accepted_date": "20170126073622",
    "sec_index_url": "https://www.sec.gov//Archives/edgar/data/816284/000110465917004128/0001104659-17-004128-index.htm",
    "sec_url": "https://www.sec.gov//Archives/edgar/data/816284/000110465917004128/0001104659-17-004128.txt",
    "metadata_file_name": "C:\Users\aaron\OneDrive\Desktop\homework\finance2\SEC-EDGAR-text\output_files_examples\batch_0006\003\CELG_0000816284_EX991_20170126_EX-99_metadata.json",
    "original_file_name": "",
    "original_file_size": "680737 chars",
    "document_group": "EX-99",
    "section_name": "EX-99",
    "section_n_characters": 34315,
    "endpoints": [
        "Exhibit 99.1 ",
        "(3) OTEZLA® was approved in the U.S. for Psoriatic Arthritis in March 2014 and approved in the U.S. for Psoriasis in September 2014. OTEZLA® was approved for Psoriatic Arthritis and Plaque Psoriasis in the EU in January 2015."
    ],
    "extraction_method": "html",
    "warnings": [],
    "company_description": "CELG",
    "output_file": "C:\Users\aaron\OneDrive\Desktop\homework\finance2\SEC-EDGAR-text\output_files_examples\batch_0006\003\CELG_0000816284_EX991_20170126_EX-99_excerpt.txt",
    "time_elapsed": 0.2,
    "batch_number": 6,
    "batch_signature": "",
    "batch_start_time": "2023-04-16 22:00:52.115412",
    "batch_machine_id": "DESKTOP-BTCJU5K",
    "section_end_time": "2023-04-16 22:09:59.703432"
}